Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcicor
- Development stage
- Unknown
- Lead developer
- Emblazon Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Calcicor** is an oral fixed-dose bone-health product marketed by Emblazon Life Sciences. A retailer listing identifies its active constituents as coral calcium and vitamin D3, used to provide calcium and support bone strength and prevention of bone breakage. The vitamin D3 component promotes intestinal calcium absorption following metabolic activation, while coral calcium supplies calcium for mineral homeostasis and bone mineralization. ([wellnessforever.com](https://www.wellnessforever.com/product/calcicor-10tab))
- Brand names
- Calcicor
02
Targets
CNR1 (Cannabinoid receptor 1)HRH3 (Histamine Receptor H3)NR1H3 (Liver X receptor beta)NOP (Nociceptin/orphanin FQ peptide receptor)PTCH1 (Patched 1 Protein)PDE3A (Phosphodiesterase 3A)PDE5 (Phosphodiesterase 5A)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Calcicor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calcicor.